<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876484</url>
  </required_header>
  <id_info>
    <org_study_id>IJ-G2-16</org_study_id>
    <nct_id>NCT02876484</nct_id>
  </id_info>
  <brief_title>Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass</brief_title>
  <official_title>Effects of Chenodeoxycholic Acid and Colesevelam on GLP-1 Secretion, During a Meal, After Roux-en-Y Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of bile acid and bile acids sequestrants&#xD;
      on GLP-1 Secretion, during a meal, in patients after Roux-en-Y gastric bypass.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">November 2020</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GLP-1 secretion (evaluated by iAUC)</measure>
    <time_frame>-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes after mixed meal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose levels</measure>
    <time_frame>-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PYY secretion</measure>
    <time_frame>-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile acids/FGF19 concentrations</measure>
    <time_frame>-10, 0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite measurements (VAS-score)</measure>
    <time_frame>0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCM levels</measure>
    <time_frame>Baseline, 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide secretion</measure>
    <time_frame>Baseline, 0, 5, 10, 20, 30, 45, 60, 90, 120, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon secretion</measure>
    <time_frame>Baseline, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP secretion</measure>
    <time_frame>0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCK secretion</measure>
    <time_frame>0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bile acid secretion</measure>
    <time_frame>0, 10, 20, 30, 45, 60, 90, 120, 180 and 240 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Severe Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.&#xD;
25 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chenodeoxycholic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Chenodeoxycholic acid (1250 mg) mixed in 25 ml yoghurt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colesevelam x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>plus (on another study day) 3,75 g colesevelam administered the evening before the experiment. Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_label>Colesevelam x 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chenodeoxycholic Acid</intervention_name>
    <arm_group_label>Chenodeoxycholic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Uncomplicated RYGB performed minimum 3 months prior to the study.&#xD;
&#xD;
          -  Fasting plasma glucose &lt; 7,0 mM, HbA1c &lt; 48 mmol/mol 3 months after RYGB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fasting plasma glucose &gt; 7,0 mM, HbA1c &gt; 48 mmol/mol 3 months after RYGB.&#xD;
&#xD;
          -  Dysregulated thyroid diseases, use of antithyroid treatment.&#xD;
&#xD;
          -  Late diabetic complications as retinopathy, renal insufficiency, neuropathy or&#xD;
             previous pancreatitis.&#xD;
&#xD;
          -  Complications to RYGB. Documented reactive hypoglycaemia, severe dumping (vomiting,&#xD;
             diarrhea, severe abdominal pain after food intake).&#xD;
&#xD;
          -  Cholecystectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Maria Saur Svane</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

